ABOUT BAPA

Our Mission

Advocate – Educate – Communicate

We strive to organize Bangladeshi-American Pharmacists in a strong and professional platform so they can be more successful in their career and have a fulfilling experience in this country. We work to get the members involved in the socio-political process that determines their future. We hope to motivate everyone to contribute their time and talent to the betterment of the pharmacy profession here at home and in Bangladesh.

Specifically, the purpose of the organization is to foster cooperation and collaboration among Bangladeshi pharmacists residing in North America; to build and maintain relations with other pharmacists’ associations in North America, to support the profession of pharmacy in Bangladesh and in North America; to support and encourage the development of Pharmaceutical Science in Bangladesh; to develop and conduct programs for maintaining and improving the professional standards; to promote welfare of members’ families in case of need; to protect the professional interests of members of the Association.

Our Sponsors

Silver Sponsor

Silver Sponsor

Silver Sponsor

Pharmaceutical News

  • New EPIVINF study highlights a promising model for Long COVID research
    on January 19, 2026 at 4:56 pm

    Researchers from IRTA and IrsiCaixa, partners in the EPIVINF project, have identified the golden Syrian hamster as a potential relevant model for studying the biology of long COVID, also known as post-COVID-19 condition (PCC). Long COVID is not a single disease but a complex syndrome involving a range of persistent symptoms. People suffering from it report overwhelming fatigue, memory lapses, "brain fog," difficulty concentrating, sleep disturbances, and neurological symptoms that can last for months or even years after the initial infection.

  • Plant discovery could lead to new ways of producing medicines
    on January 16, 2026 at 9:00 am

    Plants make substances called alkaloids to protect themselves, and humans have long taken advantage of these chemicals, using them in painkillers, treatments for disease and household products such as caffeine and nicotine. By understanding how plants make these substances, researchers aim to produce new and improved chemicals for medicines more quickly, cheaply and with less environmental impact.

  • A protein found in the GI tract can neutralize many bacteria
    on January 15, 2026 at 9:00 am

    The mucosal surfaces that line the body are embedded with defensive molecules that help keep microbes from causing inflammation and infections. Among these molecules are lectins - proteins that recognize microbes and other cells by binding to sugars found on cell surfaces. One of these lectins, MIT researchers have found, has broad-spectrum antimicrobial activity against bacteria found in the GI tract.

  • New drug candidate reverses metabolic liver disease and fibrosis
    on January 14, 2026 at 9:00 am

    Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita Therapeutics that has the potential to prevent and reverse liver fibrosis - a dangerous, disease-induced build-up of scar tissue in the liver that often leads to cancer. The findings point to a potential new treatment for the millions of people living with liver disease, addressing a critical gap where no approved drugs currently exist in Canada.

  • Merck to complete acquisition of Cidara Therapeutics
    on January 13, 2026 at 9:00 am

    Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the successful completion of the cash tender offer, through a subsidiary, for all the outstanding shares of common stock of Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”).